Novo Nordisk shares rose 3.55% on Tuesday after the Danish pharmaceutical company announced a strategic collaboration with Anthropic and received a positive recommendation from a European Medicines Agency committee for Frehemgo, its haemophilia A treatment. Under the agreement, Novo will use Anthropic’s Claude Science platform to accelerate drug development and improve internal software capabilities. Neither company disclosed financial terms or identified specific therapeutic programmes for the technology. CEO Mike Doustdar said artificial intelligence could shorten the route from research to marketed products, while Anthropic CEO Dario Amodei said the partnership aims to reduce research timelines and improve patient outcomes. The collaboration follows Novo’s earlier partnerships with OpenAI and Amazon Web Services. The EMA recommendation covers adults and children with haemophilia A, including patients with or without factor VIII inhibitors, and is based on the FRONTIER programme. Frehemgo, also known as denecimig, is a factor VIIIa mimetic bispecific antibody delivered through a pre-filled pen on weekly, biweekly or monthly schedules. Novo plans launches in selected European countries in the fourth quarter of 2026, followed by a broader EU rollout from early 2027, subject to the European Commission’s decision. The company has also rebranded by dropping “Nordisk” and operating as “Novo.”